Get the Stockscreener App
7.27
6.91%
0.47
Pre-market:
7.43
0.16
+2.20%
Absci Corp stock is traded at $7.27, with a volume of 6.68M.
It is up +6.91% in the last 24 hours and up +41.72% over the past month.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
See More
Previous Close:
$6.80
Open:
$7.38
24h Volume:
6.68M
Relative Volume:
1.38
Market Cap:
$1.13B
Revenue:
$2.80M
Net Income/Loss:
$-115.18M
P/E Ratio:
-8.5802
EPS:
-0.8473
Net Cash Flow:
$-94.03M
1W Performance:
+10.99%
1M Performance:
+41.72%
6M Performance:
+114.45%
1Y Performance:
+161.51%
1-Day Range:
$7.13
$8.17
1-Week Range:
$6.07
$8.17
52-Week Range:
$2.24
$8.17
Absci Corp Stock (ABSI) Company Profile
Name
Absci Corp
Sector
Industry
Phone
(360) 949-1041
Address
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
7.27 | 1.13B | 2.80M | -115.18M | -94.03M | -0.8473 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-02-25 | Initiated | JP Morgan | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jan-22-25 | Initiated | Needham | Buy |
| Oct-02-24 | Initiated | Guggenheim | Buy |
| Jul-03-24 | Initiated | Morgan Stanley | Overweight |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-04-23 | Initiated | H.C. Wainwright | Buy |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Jul-18-22 | Initiated | Truist | Buy |
| Mar-02-22 | Resumed | Cowen | Market Perform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Nov-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Aug-16-21 | Initiated | BofA Securities | Neutral |
| Aug-16-21 | Initiated | Cowen | Market Perform |
| Aug-16-21 | Initiated | Credit Suisse | Outperform |
| Aug-16-21 | Initiated | Stifel | Hold |
View All
Absci Corp Stock (ABSI) Latest News
Absci Corp stock hits 52-week high at 7.44 USD By Investing.com - Investing.com Australia
ABSI Maintains Buy Rating -- Price Target Raised to $15.00 by Gu - GuruFocus
Absci Corp (ABSI) awards RSUs and stock options to director Szela - Stock Titan
Absci Corp stock hits 52-week high at 7.44 USD - Investing.com
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ - marketscreener.com
Guggenheim raises Absci stock price target to $15 on hair loss drug - Investing.com Nigeria
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery - 01net
Absci Insiders Land Bargain With Gains Of US$1.4m - Moomoo
Can AI crack 'undruggable' drugs? MindWalk, Absci weigh in - Stock Titan
Absci Corporation (ABSI) reports Q1 loss, misses revenue estimates - MSN
Absci (ABSI) Q1 2026 Earnings Call Transcript - AOL.com
Absci (ABSI) director Karen McGinnis granted RSUs and stock options - Stock Titan
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026Slideshow - Seeking Alpha
Absci (NASDAQ: ABSI) director Mary Szela awarded RSUs and stock options - Stock Titan
Absci (NASDAQ: ABSI) director granted RSUs and stock options in equity awards - Stock Titan
[Form 4] Absci Corp Insider Trading Activity - Stock Titan
Absci (NASDAQ: ABSI) awards director 10,100 RSUs and 39,800 options - Stock Titan
Absci (ABSI) director Joseph Sirosh awarded RSUs and 39,800-share option - Stock Titan
Absci (NASDAQ: ABSI) reports 2026 shareholder votes on directors and auditor - Stock Titan
Absci climbs after new outperform at Leerink on catalyst path - MSN
ABSI Initiates Coverage by Leerink Partners -- Rating Outperform - GuruFocus
Leerink Partners Initiates Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $12 - Moomoo
Absci Shares Rise After Leerink Partners Initiates Coverage at Outperform - Moomoo
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Absci stock granted New Outperform at Leerink (ABSI:NASDAQ) - Seeking Alpha
Absci Corp. Hits New 52-Week High of $7.33, Up 49.34% - MarketsMojo
The 1 AI Stock I'd Put in a Time Capsule and Open in 2036 - AOL.com
Absci Corp (ABSI) CFO reports 8,319-share tax withholding on RSU vesting - Stock Titan
ABSIAbsci Corp Stock Price and Quote - Finviz
Absci Corp. Stock Hits Day High with 17.83% Surge in Intraday Performance - Markets Mojo
ABSI News | ABSCI CORP (NASDAQ:ABSI) - ChartMill
BTIG Initiates Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $9 - Moomoo
This biotech is leading what could be a 'GLP-1 moment for hair loss,' says BTIG - CNBC
ABSI Initiates Coverage On BTIG -- Price Target Announced at $9. - GuruFocus
BTIG initiates Absci stock with buy rating on AI drug platform By Investing.com - Investing.com South Africa
BTIG initiates Absci stock with buy rating on AI drug platform - Investing.com Australia
This Suncrete Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Earnings call transcript: Absci Corp misses revenue forecast in Q1 2026 - Investing.com Nigeria
Absci Insiders Placed Bullish Bets Worth US$1.22m - simplywall.st
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? - AOL.com
The 1 AI stock I'd put in a time capsule and open in 2036 - MSN
Grail's Slump Enters Week 10. Is There Any End in Sight? - AOL.com
Doximity Stock Just Got Crushed. Is This a Rare Chance to Buy a High-Quality Growth Company on Sale? - AOL.com
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
2 Stocks That Could Realistically Double by 2030 - AOL.com
ABSI Price Today: Absci Corporation Stock Price, Quote & Chart | MEXC - MEXC Exchange
Absci Insider Buyers Pleased With US$700k Return On Investment - Yahoo Finance
Absci Corp Stock (ABSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Absci Corp Stock (ABSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Busch Andreas | Chief Innovation Officer |
Mar 12 '26 |
Buy |
2.29 |
100,000 |
229,000 |
421,446 |
| Pangalos Menelas N | Director |
Feb 27 '26 |
Buy |
2.74 |
75,095 |
205,760 |
189,055 |
| McClain Sean | Chief Executive Officer |
Feb 23 '26 |
Option Exercise |
1.21 |
396,399 |
479,643 |
8,730,966 |
| McClain Sean | Chief Executive Officer |
Feb 02 '26 |
Sale |
2.99 |
26,761 |
80,015 |
8,334,567 |
| Jonasson Zachariah | CFO / CBO |
Feb 02 '26 |
Sale |
2.99 |
17,496 |
52,313 |
383,538 |
| VAN HOUTEN FRANS | Director |
Dec 05 '25 |
Buy |
3.72 |
40,000 |
148,800 |
63,320 |
| Pangalos Menelas N | Director |
Sep 22 '25 |
Buy |
2.66 |
95,785 |
254,788 |
113,960 |
| Bedrick Todd | SVP, CAO |
Sep 22 '25 |
Buy |
2.70 |
10,000 |
27,000 |
180,428 |
| Busch Andreas | Chief Innovation Officer |
Jul 28 '25 |
Buy |
3.04 |
50,000 |
152,000 |
327,264 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):